Galectin Therapeutics Inc.
GALTNASDAQHealthcare● Active
$2.40
+$0.07(+3.00%)
Market Cap$158056555
P/E Ratio—
52W High$7.13
52W Low$1.27
Galectin Therapeutics Inc. (GALT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GALT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.04B | $0.03B | $0.03B | $0.02B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.02B | $0.04B | $0.04B | $0.04B | $0.03B |
| Operating Income | ($0.02B) | ($0.04B) | ($0.04B) | ($0.04B) | ($0.03B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.03B) | ($0.05B) | ($0.04B) | ($0.04B) | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.03B) | ($0.05B) | ($0.04B) | ($0.04B) | ($0.03B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | ($0.02B) | ($0.04B) | ($0.04B) | ($0.04B) | ($0.03B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Galectin Therapeutics Inc. data
About Galectin Therapeutics Inc. (GALT) Income Statement
Galectin Therapeutics Inc. (GALT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GALT reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.03B) — a net profit margin of —.
Frequently asked questions
GALT · 4 questionsGalectin Therapeutics Inc. (GALT) reported revenue of $0.00B for 2025, down —% year-over-year.
GALT revenueGALT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08